Title |
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
|
---|---|
Published in |
The Lancet, November 2012
|
DOI | 10.1016/s0140-6736(12)61134-9 |
Pubmed ID | |
Authors |
David Neal Franz, Elena Belousova, Steven Sparagana, E Martina Bebin, Michael Frost, Rachel Kuperman, Olaf Witt, Michael H Kohrman, J Robert Flamini, Joyce Y Wu, Paolo Curatolo, Petrus J de Vries, Vicky H Whittemore, Elizabeth A Thiele, James P Ford, Gaurav Shah, Helene Cauwel, David Lebwohl, Tarek Sahmoud, Sergiusz Jozwiak |
Abstract |
Tuberous sclerosis complex is a genetic disorder leading to constitutive activation of mammalian target of rapamycin (mTOR) and growth of benign tumours in several organs. In the brain, growth of subependymal giant cell astrocytomas can cause life-threatening symptoms--eg, hydrocephalus, requiring surgery. In an open-label, phase 1/2 study, the mTOR inhibitor everolimus substantially and significantly reduced the volume of subependymal giant cell astrocytomas. We assessed the efficacy and safety of everolimus in patients with subependymal giant cell astrocytomas associated with tuberous sclerosis complex. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 1 | 10% |
United Kingdom | 1 | 10% |
United States | 1 | 10% |
France | 1 | 10% |
Switzerland | 1 | 10% |
Argentina | 1 | 10% |
Unknown | 4 | 40% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 7 | 70% |
Science communicators (journalists, bloggers, editors) | 1 | 10% |
Practitioners (doctors, other healthcare professionals) | 1 | 10% |
Scientists | 1 | 10% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Spain | 3 | <1% |
United States | 3 | <1% |
Netherlands | 2 | <1% |
Korea, Republic of | 1 | <1% |
United Kingdom | 1 | <1% |
Denmark | 1 | <1% |
France | 1 | <1% |
Canada | 1 | <1% |
Poland | 1 | <1% |
Other | 0 | 0% |
Unknown | 394 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 69 | 17% |
Other | 44 | 11% |
Student > Bachelor | 40 | 10% |
Student > Master | 39 | 10% |
Student > Ph. D. Student | 34 | 8% |
Other | 107 | 26% |
Unknown | 75 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 178 | 44% |
Agricultural and Biological Sciences | 33 | 8% |
Neuroscience | 29 | 7% |
Biochemistry, Genetics and Molecular Biology | 23 | 6% |
Nursing and Health Professions | 15 | 4% |
Other | 35 | 9% |
Unknown | 95 | 23% |